Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Period	PE Ratio
2020-12-31	-14.22
2021-12-31	-91.72
2022-12-31	-24.38
2023-12-31	-13.30
2024-12-31	-20.02

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARS	$61.45	+0.79%	0.72M
3
4
5

Tarsus Pharmaceuticals Inc. (TARS) PE Ratio

PE Ratio Data

Get Tarsus Pharmaceuticals Inc. Data in Excel

More TARS Financial Data